New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately t...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Guidelines for Infection Control in the Urological Field, including Urinary Tract Management (revised second edition)
The Committee for the Development of Guidelines for Infection Control in the Urological Field, including Urinary Tract Management of the Japanese Urological Association, together with its systematic review team and external reviewers, have prepared a set of practice guidelines, an abridged version of which is published herein. These guidelines cover the following topics: (i) foundations of infection control, standard precautions, route-specific precautions, and occupational infection control (including vaccines); (ii) the relationship between urologists and infection control; (iii) infection control in urological wards and...
Source: Current Awareness Service for Health (CASH) - October 15, 2021 Category: Consumer Health News Source Type: news

The Evolution of HBV, From Hunter-Gatherers to Today The Evolution of HBV, From Hunter-Gatherers to Today
The prehistoric origins of hepatitis B virus are painted in new color by this study analyzing the largest ever dataset of ancient viral genomes.Quick Take (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 8, 2021 Category: Gastroenterology Tags: Infectious Diseases News Source Type: news

Progress Toward Hepatitis B Control, European Region Progress Toward Hepatitis B Control, European Region
This report details the progress made during 2016-2019 in immunization and screening for hepatitis B in the EUR.Morbidity & Mortality Weekly Report (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 8, 2021 Category: Consumer Health News Tags: Public Health & Prevention Journal Article Source Type: news

YouTube bans all anti-vaccine misinformation
The new policy expands the rules to misleading claims about long-approved vaccines, such as those against measles and hepatitis B, as well as to falsehoods about vaccines in general. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - September 30, 2021 Category: Health Management Authors: Davey Alba Source Type: news

YouTube bans all anti-vaccine misinformation
The new policy expands the rules to misleading claims about long-approved vaccines, such as those against measles and hepatitis B, as well as to falsehoods about vaccines in general. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 30, 2021 Category: Biotechnology Authors: Davey Alba Source Type: news

YouTube Bans Anti-Vaccine Misinformation
The new set of policies will cover not just the Covid-19 vaccines or long-approved vaccines against diseases like measles and hepatitis B, but also general claims about vaccines, YouTube said. (Source: NYT Health)
Source: NYT Health - September 29, 2021 Category: Consumer Health News Authors: Davey Alba Tags: YouTube.com Vaccination and Immunization Rumors and Misinformation Coronavirus (2019-nCoV) Kennedy, Robert F Jr Mercola, Joseph M (1954- ) Children ' s Health Defense Social Media Source Type: news

Tim Block to step down as president of Hepatitis B Foundation, Pennsylvania Biotechnology Center
Both Bucks County organizations are promoting from within in naming their future presidents. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - September 27, 2021 Category: Biotechnology Authors: John George Source Type: news

The Effects of HBV Infection on Natural and IVF Pregnancy The Effects of HBV Infection on Natural and IVF Pregnancy
A new study examines the potential impacts of hepatitis B virus on pregnancy complications and outcomes among women undergoing IVF.Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Africa: Messenger RNA - How It Works in Nature and in Making Vaccines
[The Conversation Africa] Vaccines have long been an integral part of public health programmes around the world, reducing the spread and severity of infectious diseases. The success of immunisation strategies to protect children from diseases like polio, hepatitis B, and measles, and adults from influenza and pneumococcal disease, can be seen globally. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - September 7, 2021 Category: African Health Source Type: news

Fraction of Cirrhosis and HCC Attributable to Hepatitis B and C Fraction of Cirrhosis and HCC Attributable to Hepatitis B and C
This study assessed a protocol developed by WHO to collect data on the worldwide fraction of cirrhosis and hepatocellular carcinoma attributable to hepatitis B and C. How might it be improved?Journal of Viral Hepatitis (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 6, 2021 Category: Surgery Tags: Gastroenterology Journal Article Source Type: news

Estimating cost effectiveness of hepatitis B vaccination in US adults
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 1, 2021 Category: Drugs & Pharmacology Source Type: news

Algorithm for the Use of Transient Elastography in HBV Algorithm for the Use of Transient Elastography in HBV
This study aimed to validate guidelines issued by EASL/ALEH regarding the use of transient elastography for quantifying liver fibrosis in patients with chronic hepatitis B.Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 30, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

HBV Screen Often Incomplete Before Tocilizumab, Tofacitinib Used HBV Screen Often Incomplete Before Tocilizumab, Tofacitinib Used
About three quarters of patients starting either drug in a single health system did not undergo complete hepatitis B virus screening beforehand.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - August 10, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Source Type: news

Progress Toward Hepatitis B Control - World Health Organization European Region, 2016-2019
This report describes progress toward hepatitis B control in the World Health Organization European Region. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - July 29, 2021 Category: American Health Tags: Hepatitis B Hepatitis B Vaccination MMWR Morbidity & Mortality Weekly Report Source Type: news

Nigeria: 18 Million Nigerians Infected With Hepatitis - Govt
[Daily Trust] About 18 million Nigerians are estimated to be infected with hepatitis B and C, the Minister of Health, Dr Osagie Ehanire has said. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - July 29, 2021 Category: African Health Source Type: news

Recognizing Hepatitis R & D on World Hepatitis Day
Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. There are five main hepatitis viruses, with types A, B, C most common. In 2018, the Centers for Disease Control and Prevention estimated that Americans were infected with 24,900 cases of hepatitis A and 21,600 cases of hepatitis B, many of which go undiagnosed because individuals do not know they are infected. Over the past several years, the biopharmaceutical industry has made significant progress in bringing medicines to patients that improve cure rates, reduce side effects and duration of treatment and expand treatment options. (Source: The Catalyst)
Source: The Catalyst - July 28, 2021 Category: Pharmaceuticals Tags: Research and Development Drug Cost Hepatitis C Source Type: news

New Antiviral Drug Promising Against HBV New Antiviral Drug Promising Against HBV
A hepatitis B virus core protein allosteric modulator appears safe and shows antiviral action in patients with chronic HBV infection, according to a small company-funded study.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 21, 2021 Category: Gastroenterology Tags: Infectious Diseases News Source Type: news

European Duplicity Undermines Anti-Pandemic Efforts
By Anis Chowdhury and Jomo Kwame SundaramSYDNEY and KUALA LUMPUR, Jul 20 2021 (IPS) Despite facing the world’s worst pandemic of the last century, rich countries in the World Trade Organization (WTO) have blocked efforts to enable more affordable access to the means to fight the pandemic. Everyone knows access for all to the means for testing, treatment and prevention – including diagnostic tests, therapeutic medicines, personal protective equipment and vaccines – is crucial. Anis ChowdhuryEuropean deceit In October 2020, South Africa and India requested the WTO to temporarily suspend relevant provisions...
Source: IPS Inter Press Service - Health - July 20, 2021 Category: International Medicine & Public Health Authors: Anis Chowdhury and Jomo Kwame Sundaram Tags: Aid Development & Aid Economy & Trade Global Headlines Health Human Rights Humanitarian Emergencies TerraViva United Nations Jomo Kwame Sundaram & Anis Chowdhury Source Type: news

New COVID-19 vaccine candidate provides effective option for low- to mid-income countries
(Emory Health Sciences) Combining yeast-expression technology and a novel adjuvant formulation to produce a COVID-19 vaccine candidate is effective against SARS-COV-2 and promises to be easy to produce at large scale and cost-effective, important aspects for vaccinating people worldwide, especially in low- to middle-income countries. Results from the study, which applied lessons learned from the hepatitis b vaccine platform technology, are published online today in Science Immunology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 15, 2021 Category: International Medicine & Public Health Source Type: news

Hepatitis B Virus Monitoring Needed After Liver Transplantation
FRIDAY, July 9, 2021 -- Health care providers should test liver recipients for hepatitis B virus (HBV) given the slight risk for unexpected donor-derived HBV infection, according to research published in the July 9 issue of the U.S. Centers for... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 9, 2021 Category: Pharmaceuticals Source Type: news

Unexpected Hepatitis B Virus Infection After Liver Transplantation - United States, 2014-2019
This report describes donor-derived hepatitis B virus infections after liver transplantation. (Source: CDC Morbidity and Mortality Weekly Report)
Source: CDC Morbidity and Mortality Weekly Report - July 8, 2021 Category: American Health Tags: Hepatitis B MMWR Morbidity & Mortality Weekly Report Organ Translplants Source Type: news

Punjab introduces free testing, treatment of Hepatitis B in all govt health institutions
"Hepatitis B samples will be taken at these institutions from the patient free of cost, while the cost of the test will be reimbursed to the lab at the rate of Rs 851 by the state government," he said, as per an official statement. (Source: The Economic Times)
Source: The Economic Times - June 22, 2021 Category: Consumer Health News Source Type: news

A third dose of COVID-19 vaccine increased antibody levels in organ transplant recipients with a sub
(American College of Physicians) A case series published in Annals of Internal Medicine found that a third dose of vaccine increased antibody levels in organ transplant recipients who had suboptimal response to standard vaccination. These findings suggest that clinical trials are warranted to determine whether booster doses should be incorporated into clinical practice for transplant patients, just as they have been for hepatitis B and influenza vaccinations. This is the first study to report on response to a third vaccine dose. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - June 14, 2021 Category: Infectious Diseases Source Type: news

Two-dose hepatitis B vaccine cost effective versus 3-dose vaccine
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

New immunotherapy 'highly effective' against hepatitis B
(University College London) Scientists at UCL have identified a new immunotherapy to combat the hepatitis B virus (HBV), the most common cause of liver cancer in the world. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 14, 2021 Category: International Medicine & Public Health Source Type: news

Treatment Paradigm for Chronic HBV in Flux Treatment Paradigm for Chronic HBV in Flux
These days deciding when to stop targeted treatment for chronic hepatitis B is a bigger challenge than knowing when to start, Norah A. Terrault, MD, MPH, observed.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - April 3, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

ART Likely Less Effective in Women With HIV Versus Other Chronic Viral Illnesses ART Likely Less Effective in Women With HIV Versus Other Chronic Viral Illnesses
HIV-infected women who underwent assisted reproductive technology (ART) had a lower live birth rate than those with chronic hepatitis B or hepatitis C virus in a cohort study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 1, 2021 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

How DaVita is working to directly administer Covid-19 vaccines to patients across the country
The Denver-based kidney care company is using the processes it developed for flu and Hepatitis B vaccines and applying them to Covid-19. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 30, 2021 Category: American Health Authors: Jensen Werley Source Type: news

How DaVita is working to directly administer Covid-19 vaccines to patients across the country
The Denver-based kidney care company is using the processes it developed for flu and Hepatitis B vaccines and applying them to Covid-19. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 30, 2021 Category: Biotechnology Authors: Jensen Werley Source Type: news

Hepatitis B: What people can learn from donkeys
(German Center for Infection Research) The discovery of a previously unknown hepatitis B virus in donkeys and zebras opens up new opportunities for understanding the course of the disease. A global research consortium was able to show that the course of the infection with this virus is similar to that of chronic hepatitis B in humans. The study was led by DZIF scientists at the Charit é - Universit ä tsmedizin Berlin and the Justus Liebig University Giessen. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 17, 2021 Category: International Medicine & Public Health Source Type: news

New study provides detailed view of how hepatitis B virus establishes chronic infection
(Princeton University) Researchers identified five proteins that are necessary for hepatitis B virus infection, which kills more than 850,000 people worldwide each year and has no cure. The research on the viral life cycle could eventually help identify drugs that block infection. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 11, 2021 Category: International Medicine & Public Health Source Type: news

Venatorx adds potential chronic hepatitis B treatment to its pipeline
A Chester County pharmaceutical company said Wednesday it has selected a clinical candidate it intends to develop as a treatment for chronic hepatitis B virus infections. Venatorx Pharmaceuticals, an antibiotic developer that was founded in 2010 and is based in Malvern, has long had hepatitis B on its list of targets. An estimated 200,000 new cases of hepatitis B, a serious liver infection, are diagnosed in the U.S each year. More than 250 million people worldwide have chronic hepatitis B. Venatorx's… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 10, 2021 Category: American Health Authors: John George Source Type: news

Ghana: Stakeholders Call for Hepatitis B, Malaria Testing Guidelines
[Ghanaian Times] Stakeholders at a Hepatitis B and Malaria (HEPMAL) workshop yesterday called for a National Testing Guidelines for the eradication of Hepatitis B and Malaria. (Source: AllAfrica News: Malaria)
Source: AllAfrica News: Malaria - March 8, 2021 Category: Infectious Diseases Source Type: news

Risk Factors for Development of HCC in Chronic HBV Infection Risk Factors for Development of HCC in Chronic HBV Infection
How do various metabolic factors and comorbidities influence hepatocellular carcinoma risk in patients with chronic hepatitis B infection?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 4, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

New combination therapy offers chance of healing hepatitis B
(German Center for Infection Research) Around 260 million people, more than three percent of the global population, are chronically infected with the hepatitis B virus (HBV); in the long term, this often leads to complications such as liver cirrhosis and liver cancer. A cure is not yet possible with the available medication. Scientists at the German Center for Infection Research (DZIF) and the University Hospital Eppendorf (UKE) have now investigated a new combination therapy that has proven highly effective in their infection model. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - February 4, 2021 Category: Infectious Diseases Source Type: news

New biosensors quickly detect coronavirus proteins and antibodies
(University of Washington Health Sciences/UW Medicine) Researchers have designed protein-based biosensors that glow when mixed with targeted molecules, such as components of the pandemic coronavirus or specific COVID-19 antibodies. This development could allow for faster, more widespread testing in the near future. Similar biosensors could be designed to detect medically relevant human proteins such as Her2 (a biomarker for some breast cancers) and Bcl-2 (which has clinical significance in some other cancers), as well as a bacterial toxin and antibodies that target Hepatitis B virus. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 28, 2021 Category: Cancer & Oncology Source Type: news

Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV
TITUSVILLE, N.J., January 21, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen’s 25-year commitment to make HIV history. In the U.S., ViiV Healthcare is the marketing authorization holde...
Source: Johnson and Johnson - January 22, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Health - January 11, 2021 Category: Consumer Health News Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

mRNA Technology Gave Us the First COVID-19 Vaccines. It Could Also Upend the Drug Industry
“No!” The doctor snapped. “Look at me!” I had been staring her in the eyes, as she had ordered, but when a doctor on my other side began jabbing me with a needle, I started to turn my head. “Don’t look at it,” the first doctor said. I obeyed. This was in early August in New Orleans, where I had signed up to be a participant in the clinical trial for the Pfizer-BioNTech COVID-19 vaccine. It was a blind study, which meant I was not supposed to know whether I had gotten the placebo or the real vaccine. I asked the doctor if I would really been able to tell by looking at the syringe. &...
Source: TIME: Science - January 11, 2021 Category: Science Authors: Walter Isaacson Tags: Uncategorized COVID-19 feature Magazine Source Type: news

New viral detection technique uses smartphone camera to diagnose various infections
(American Association for the Advancement of Science) Scientists have developed a novel smartphone-based technique to diagnose viral infections that uses a deep learning algorithm to identify viruses in metal nanoparticle-labeled samples, enabling rapid virus detection without the need for skilled laboratory workers and expensive equipment. The system correctly identified clinically relevant concentrations of Zika, hepatitis B (HBV), or hepatitis C (HCV) in 134 patient samples with 98.97% sensitivity. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 16, 2020 Category: Infectious Diseases Source Type: news

USPSTF Recommends Hep B Screen for At-Risk Teens, Adults
TUESDAY, Dec. 15, 2020 -- The U.S. Preventive Services Task Force (USPSTF) concludes that screening adults and adolescents at increased risk for hepatitis B virus (HBV) infection has moderate net benefit. These findings form the basis of a final... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 15, 2020 Category: Pharmaceuticals Source Type: news

USPSTF statement on screening for hepatitis B virus infection in adolescents, adults
(JAMA Network) The   US Preventive Services Task Force (USPSTF) recommends screening for hepatitis B virus   infection in adolescents and adults at increased risk for infection.   (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 15, 2020 Category: Infectious Diseases Source Type: news

The Ambulance Science Podcast: Make Up Your Own Mind About the Vaccine
Get every episode of The Ambulance Science Podcast by subscribing to Apple Podcasts or Google Podcasts. Where I’m coming from (compared to most of my colleagues): Master’s in Public Health with a concentration in Health Policy from Yale Medical School.FT Faculty at GWU School of Medicine & Southern Connecticut State University MPH Program, and long-time adjunct faculty at NYMC MPH program in Health Policy.Assistant Commissioner of Health at the NYC Department of Health & Mental Hygiene during the first SARS outbreak.Served as State EMS Director, Consultant to Public Health ...
Source: JEMS Special Topics - December 14, 2020 Category: Emergency Medicine Authors: JEMS Staff Tags: Podcasts Ambulance Science Source Type: news

Aspirin and Statins in Chronic Hepatitis B: It's Complicated Aspirin and Statins in Chronic Hepatitis B: It's Complicated
Statins play a bigger part than aspirin in reducing risk for hepatocellular carcinoma in patients with hepatitis B, new research shows, and cirrhosis seems to cancel any beneficial effect of aspirin.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 19, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Mixed Outcomes in Tenofovir Trial for Chronic Hepatitis B Mixed Outcomes in Tenofovir Trial for Chronic Hepatitis B
Levels of surface antigen loss were low whether or not patients treated with tenofovir also received interferon, but some patients met criteria for inactive chronic disease after therapy withdrawal.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Researchers discover enzyme suppressing immune response to viral infections
(University of Missouri-Columbia) Viruses such as HIV, hepatitis B and hepatitis C evade or disrupt the immune system to create persistent infections. These viruses remain a serious health threat, but researchers from the University of Missouri School of Medicine have discovered how an enzyme that regulates several cellular processes might be a key target to preventing viruses from disarming the human immune response. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 10, 2020 Category: Cancer & Oncology Source Type: news

Sexually transmitted infections in women deprived of liberty in Roraima, Brazil - Benedetti MSG, Nogami ASA, Costa BB, Fons êca HIF, Costa IDS, Almeida IS, Miranda L, Conchy MMM, Bentes RS, Higa SN, Israel TS, Fonseca AJ.
OBJECTIVE: To evaluate the prevalence of HIV, syphilis and hepatitis B infection among women deprived of liberty in the state of Roraima, Brazil, and its correlation with perceptions, knowledge and behavioral factors. METHOD: This is a cross-sectional ... (Source: SafetyLit)
Source: SafetyLit - November 7, 2020 Category: International Medicine & Public Health Tags: Risk Factor Prevalence, Injury Occurrence Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Investor Update - November 2, 2020 Category: Pharmaceuticals Source Type: news